About this event
AI and ML models are revolutionizing antibody discovery, generating thousands of promising variants in minutes. However, downstream wet-lab validation relies on slow, expensive, and capacity-limited mammalian expression and SPR workflows. This creates a massive bottleneck, forcing teams to over-invest time and budget into candidates that ultimately fail to bind.
In this exclusive launch webinar, Sumit Kalsi, Associate Director of Product Research at Nuclera, will unveil a breakthrough solution: Nuclera's Rapid Antibody Screening Service. He will demonstrate how integrating a 96-plex cell-free binary expression and yes/no binding screen can act as the ultimate early filter for your pipeline.
Attendees will discover how to convert in-silico designs into decision-grade wet-lab data in just 14 business days—from ~$100 per antibody. Sumit will showcase validation data proving that cell-free produced IgG1 antibodies accurately reproduce CHO binding profiles, allowing teams to reserve expensive mammalian scale-up exclusively for winning candidates.
Nuclera empowers researchers to accelerate discovery with rapid, in-house access to high-quality functional proteins.
